Jim Simons Gain Therapeutics, Inc. Transaction History
Renaissance Technologies LLC
- $56.7 Billion
- Q2 2024
A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 118,700 shares of GANX stock, worth $269,449. This represents 0.0% of its overall portfolio holdings.
Number of Shares
118,700
Previous 46,700
154.18%
Holding current value
$269,449
Previous $176,000
14.2%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding GANX
# of Institutions
29Shares Held
3.69MCall Options Held
0Put Options Held
0-
Timelo Investment Management Inc.605KShares$1.37 Million0.45% of portfolio
-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$1.34 Million0.1% of portfolio
-
Dme Capital Management, LP New York, NY566KShares$1.29 Million0.04% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL450KShares$1.02 Million0.0% of portfolio
-
Hohimer Wealth Management, LLC330KShares$749,1000.1% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $27M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...